Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.52 |
| ▸ | F2 | P00734 | 9/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7558630 | 0.99 | F10 (0.51) | F10PRSS1F2OPRK1S1PR3 | |
| SCHEMBL6556978 | 0.90 | F10 (0.64) | F10PRSS1F2 | |
| SCHEMBL7560669 | 0.90 | F10 (0.56) | F10PRSS1F2S1PR3S1PR1 | |
| Hydrochloric Acid SCHEMBL7563536 | 0.89 | F10 (0.63) | F10PRSS1F2 | |
| Hydrochloric Acid SCHEMBL7558802 | 0.89 | F10 (0.56) | F10PRSS1F2S1PR3S1PR1 | |
| SCHEMBL2999019 | 0.86 | F10 (0.52) | F10PRSS1F2 | |
| SCHEMBL7561266 | 0.86 | F10 (0.50) | F10PRSS1F2S1PR3S1PR1 | |
| Hydrochloric Acid SCHEMBL7558685 | 0.85 | F10 (0.49) | F10PRSS1F2S1PR3S1PR1 | |
| SCHEMBL6555861 | 0.85 | F10 (0.45) | F10PRSS1F2 | |
| Hydrochloric Acid SCHEMBL6556499 | 0.84 | F10 (0.44) | F10PRSS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | F10 35/4885PRSS1 776/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.